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CA-RhoA mice show increased tolerance against I/R injury in vivo and 
























Characterization of conditional cardiac-specif-
ic RhoA transgenic mice. (A) Top panel: time 
line of Dox administration and sacrifice of ani-
mals for analysis. Bottom panel: activation and 
expression of endogenous (WT) and trans-
genic (HA-tagged) RhoA in the LV of CA-RhoA 
mouse hearts from lines 7 and 25 at various 
times after Dox removal (off Dox). (B) Represen-
tative image of hearts from tTA and CA-RhoA 
(line 25) mice (top panel). Scale bar: 5 mm. 
Heart weight (HW) to body weight (BW) ratio 
and heart weight to tibial length (TL) ratio from 
WT, tTA, and CA-RhoA mice at 8 weeks or 
8 months after Dox removal. Data are shown 
as mean ± SEM. (C) Representative staining 
of histological sections in tTA and CA-RhoA 
(line 25) hearts by H&E staining (top). Scale 
bars: 2 mm. Tri staining (middle) and TRITC-
conjugated, WGA staining of cell membranes 
(bottom). Scale bars: 50 μm.
Figure 2
RhoA activation protects against I/R injury in vivo. WT, tTA, and CA-RhoA 
mice (8 weeks off Dox) were subjected to in vivo I/R. (A) Quantita-
tive analyses of AAR as a percentage of ventricular area and (B) 
infarct size as a percentage of AAR of hearts subjected to in vivo I/R. 
*P < 0.001 versus WT/tTA (n = 5). Data are shown as mean ± SEM.
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CA-RhoA hearts show no alteration in activation of AKT, FAK, ERK, PKN, 





























RhoA activation protects against I/R injury in the isolated perfused heart. WT, tTA, and CA-RhoA mice (8 weeks off Dox) were subjected to 
global I/R. (A) Time course recovery of contractility following ischemia measured by LVDP, +dP/dt, and –dP/d. *P < 0.001 versus WT/tTA (n = 7). 
(B) LDH release to the coronary effluent following 45 minutes reperfusion. WT and tTA were not significantly different, and data were pooled 
together as WT/tTA. *P < 0.001 versus WT/tTA (n = 6). (C) Representative TTC-stained heart sections (top) and quantitative analysis of infarct 
size (bottom). *P < 0.001 versus WT or tTA (n = 6–7). (D and E) The LV of the WT/tTA and CA-RhoA hearts were fractioned following 30 min-
utes I/30 minutes R, and cytosolic (cyto) and mitochondrial (mito) cytochrome c (cyto c) were analyzed by Western blots. (D) Representative 
blots showing cyto (top) and mito (bottom) cytochrome c level. (RhoGDI and VDAC were used as cytosolic and mitochondrial loading control, 
respectively. VDAC was not detected in the cytosol fraction and RhoGDI was not detected in the mitochondrial fraction.) (E) Quantification of 
cytochrome c release in the cytosolic fraction. *P < 0.05 (n = 4). Data are shown as mean ± SEM.
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RhoA and PKD are activated during oxidative stress and induce protection 















PKD inhibition reverses RhoA-mediated protection against I/R injury 
in the heart. We reported previously that I/R activates RhoA in the 
isolated perfused mouse heart (5). Here we extended these find-













Cardiac-specific RhoA knockout mice (RhoAfl/fl,βMHC-cre) show decreased toler-



























nPKC isozymes and PKD are 
activated in CA-RhoA hearts. 
(A) Representative blots and 
quantification of cytosolic and 
particulate PKCα, PKCδ, and 
PKCε fractionated from the 
LV of WT, tTA, and CA-RhoA 
hearts (8 weeks off Dox). 
*P < 0.01 (n = 3–6). (B) PKD 
phosphorylation (pPKD) and 
expression in LV lysates 
from WT, tTA, and CA-RhoA 
hearts (8 weeks off Dox). 
*P < 0.01 (n = 6). Data are 
shown as mean ± SEM.
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RhoA induces PKD activation in 
NRVMs. (A) Adenoviral expression 
of RhoA induces PKD phosphoryla-
tion. (B) A Rho activator calpeptin 
(1 unit/ml, 30 minutes) induces PKD 
phosphorylation, which is inhibited by 
RhoA inactivation with C3 (2 μg/ml, 
18 hours). *P < 0.05 versus calpeptin 
(n = 3–4). (C) Time course activation 
of RhoA and PKD in response to H2O2 
(150 μM) treatment (n = 3–5). (D) Top 
panel: PKD knockdown by siRNA (90% 
knockdown). Bottom panel: treatment 
with C3 (1 μg/ml), CID755673 (50 μM), 
or PKD siRNA potentiates cell death 
induced by H2O2 (150 μM, 20 hours). 
*P < 0.05 versus vehicle H2O2 (n = 4–5). 
Data are shown as mean ± SEM.
Figure 6
RhoA and PKD are activated in response to ex vivo I/R in the heart. Effects of I/R on 
RhoA activation and PKD phosphorylation. (A) Representative blots showing time 
course of RhoA activation and PKD phosphorylation in response to I/R in the iso-
lated perfused WT mouse hearts. (B) Quantification of change in RhoA activation 
and PKD phosphorylation by 30-minute ischemia followed by 30-minute reperfusion. 
*P < 0.05 versus preischemic control (n = 3 to 4). Data are shown as mean ± SEM.
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PKD inhibition enhances I/R injury and reverses cardioprotection in 
the CA-RhoA heart. WT, tTA, and CA-RhoA hearts were perfused with 
PKD inhibitor CID755673 (50 μM) or DMSO for 30 minutes before 
I/R. (A) LDH release to the coronary effluent following 45-minute 
reperfusion. *P < 0.005 versus DMSO (n = 5–9). (B) Representative 
TTC-stained ventricular sections (top); quantitative analysis of infarct 
size (bottom). *P < 0.005 versus DMSO (n = 5–9). Sham, WT/tTA 
mouse hearts subjected to perfusion without ischemia with DMSO or 
CID755673. Data are shown as mean ± SEM.
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Cardiac-specific RhoA knockout enhances I/R injury in the heart. (A) Representative blots showing RhoA expression in RhoAfl/fl and RhoAfl/fl,βMHC-cre 
hearts. (B) Representative blots and quantification showing PKD autophosphorylation in RhoAfl/fl and RhoAfl/fl, βMHC-cre hearts following I/R. *P < 0.05 
(n = 3–4). (C and D) WT, βMHC-cre, RhoAfl/fl, and RhoAfl/fl,βMHC-cre hearts were subjected to global I/R. (C) LDH release to the coronary effluent 
following 45-minute reperfusion. *P < 0.05 versus controls (n = 4–5). (D) Representative TTC-stained ventricular sections (top); quantitative 
analysis of infarct size (bottom). *P < 0.05 (n = 4–7). Data are shown as mean ± SEM.
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